Phase I trial, Quotient code: QSC205601

Phase 1

• Conditions: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.; Not Applicable

• Registration Number: ISRCTN10521680
• Lead Sponsor: ovartis (Switzerland)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-02-01
• Last Update Posted: 21 February 2022
• Study Completion: 2022-10-06

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 116

Inclusion Criteria

Healthy human volunteer

Exclusion Criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.

Study & Design

• Study Type: Other
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.

Secondary Outcome Measures

Name	Time	Method
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.